Eisai’s lecanemab slows decline in Alzheimer’s patients with alpha-synuclein co-pathology in substudy
BIIB•Eisai and Biogen presented results from a Clarity AD substudy showing Leqembi slowed clinical decline versus placebo over 18 months in early Alzheimer’s disease patients, including those with alpha-synuclein co-pathology.
1. Substudy results
Eisai and Biogen presented Clarity AD substudy results for Leqembi at the 2026 Clinical Trials on Alzheimer's Disease conference. Over 18 months, Leqembi slowed clinical decline versus placebo in early Alzheimer's disease, including among patients with alpha-synuclein co-pathology. The subgroup findings came from an exploratory post hoc analysis.




